Aspirin Has Potential Benefits for Primary Prevention of Cardiovascular Outcomes in Diabetes: Updated Literature-Based and Individual Participant Data Meta-Analyses of Randomized Controlled Trials

Abstract

Background The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials. Methods Randomised …